

# Lauren Averett Byers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2768403/publications.pdf>

Version: 2024-02-01

126  
papers

15,137  
citations

38742

50  
h-index

20358

116  
g-index

134  
all docs

134  
docs citations

134  
times ranked

22234  
citing authors

#	ARTICLE	IF	CITATIONS
1	Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 109.	8.6	7
2	Dynamic expression of Schlafen 11 (SLFN11) in circulating tumour cells as a liquid biomarker in small cell lung cancer. <i>British Journal of Cancer</i> , 2022, 127, 569-576.	6.4	8
3	Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 172.	8.6	2
4	AXL Inhibition Induces DNA Damage and Replication Stress in Non-Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. <i>Molecular Cancer Research</i> , 2021, 19, 485-497.	3.4	32
5	The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. <i>British Journal of Cancer</i> , 2021, 124, 857-859.	6.4	26
6	Dual Inhibition of MEK and AXL Targets Tumor Cell Heterogeneity and Prevents Resistant Outgrowth Mediated by the Epithelial-to-Mesenchymal Transition in NSCLC. <i>Cancer Research</i> , 2021, 81, 1398-1412.	0.9	16
7	Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	33
8	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
9	Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients. <i>Cancers</i> , 2021, 13, 1250.	3.7	7
10	Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. <i>Cancer Cell</i> , 2021, 39, 346-360.e7.	16.8	422
11	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, 531-540.	2.6	15
12	A Reversible Shift of Driver Dependence from EGFR to Notch1 in Non-Small Cell Lung Cancer as a Cause of Resistance to Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2021, 13, 2022.	3.7	5
13	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
14	Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers. <i>Nature Communications</i> , 2021, 12, 2606.	12.8	41
15	Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study. <i>Clinical Cancer Research</i> , 2021, 27, 3884-3895.	7.0	40
16	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing. <i>Cancer Discovery</i> , 2021, 11, 2506-2523.	9.4	68
17	New Therapies and Biomarkers: Are We Ready for Personalized Treatment in Small Cell Lung Cancer?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e276-e285.	3.8	7
18	Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1821-1839.	1.1	34

#	ARTICLE	IF	CITATIONS
19	Abstract 384: Detection of DNA replication blocker SLFN11 in tumor tissue and circulating tumor cells to predict platinum response in small cell lung cancer. <i>Cancer Research</i> , 2021, 81, 384-384.	0.9	4
20	A wake-up call for cancer DNA damage: the role of Schlafen 11 (SLFN11) across multiple cancers. <i>British Journal of Cancer</i> , 2021, 125, 1333-1340.	6.4	22
21	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3633-3644.	1.6	27
22	Targeting MYC-enhanced glycolysis for the treatment of small cell lung cancer. <i>Cancer &amp; Metabolism</i> , 2021, 9, 33.	5.0	20
23	Alternative Energy: Breaking Down the Diverse Metabolic Features of Lung Cancers. <i>Frontiers in Oncology</i> , 2021, 11, 757323.	2.8	9
24	Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. <i>Nature Communications</i> , 2021, 12, 6655.	12.8	24
25	SLFN11 biomarker status predicts response to lurbinectedin as a single agent and in combination with ATR inhibition in small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 4095-4105.	2.8	17
26	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 266-273.	1.1	58
27	Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. <i>Journal of Thoracic Oncology</i> , 2020, 15, 274-287.	1.1	95
28	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	1.1	97
29	Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 98, 106445.	0.8	1
30	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1919-1927.	1.1	53
31	Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+ T cell exhaustion. <i>Nature Communications</i> , 2020, 11, 4520.	12.8	218
32	NOTCH1 Signaling in Head and Neck Squamous Cell Carcinoma. <i>Cells</i> , 2020, 9, 2677.	4.1	37
33	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. <i>PLoS ONE</i> , 2020, 15, e0234505.	2.5	25
34	STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype. <i>Journal of Thoracic Oncology</i> , 2020, 15, 777-791.	1.1	94
35	This Is Our Cells Under Pressure: Decreased DNA Damage Repair in Response to Targeted Therapies Facilitates the Emergence of Drug-Resistant Clones. <i>Cancer Cell</i> , 2020, 37, 5-7.	16.8	3
36	The MEK5-ERK5 Kinase Axis Controls Lipid Metabolism in Small-Cell Lung Cancer. <i>Cancer Research</i> , 2020, 80, 1293-1303.	0.9	49

#	ARTICLE	IF	CITATIONS
37	Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Network Open, 2020, 3, e203277.	5.9	15
38	Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. Journal of Thoracic Oncology, 2020, 15, 1449-1459.	1.1	109
39	Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. Nature Cancer, 2020, 1, 423-436.	13.2	218
40	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
41	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
42	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
43	Comparative genomics of high grade neuroendocrine carcinoma of the cervix. , 2020, 15, e0234505.		0
44	MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. Nature Communications, 2019, 10, 3485.	12.8	54
45	PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?. Journal of Thoracic Oncology, 2019, 14, 1323-1326.	1.1	7
46	Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. Journal of Thoracic Oncology, 2019, 14, 2152-2163.	1.1	80
47	Metabolic Diversity in Human Non-Small Cell Lung Cancer Cells. Molecular Cell, 2019, 76, 838-851.e5.	9.7	119
48	Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?. Cancer Discovery, 2019, 9, 1340-1342.	9.4	7
49	Reply to F. Liang. Journal of Clinical Oncology, 2019, 37, 259-259.	1.6	1
50	ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism. Science Translational Medicine, 2019, 11, .	12.4	42
51	Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. Nature Reviews Cancer, 2019, 19, 289-297.	28.4	692
52	Integrated Approaches for the Use of Large Datasets to Identify Rational Therapies for the Treatment of Lung Cancers. Cancers, 2019, 11, 239.	3.7	0
53	PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers. Clinical Cancer Research, 2019, 25, 3759-3771.	7.0	265
54	Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. Cancer Discovery, 2019, 9, 646-661.	9.4	555

#	ARTICLE	IF	CITATIONS
55	High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer. , 2019, 7, 351.		39
56	ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer. EBioMedicine, 2019, 39, 5-6.	6.1	2
57	Evading the STING: LKB1 Loss Leads to STING Silencing and Immune Escape in KRAS-Mutant Lung Cancers. Cancer Discovery, 2019, 9, 16-18.	9.4	36
58	Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era. Cancer, 2019, 125, 496-498.	4.1	3
59	Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies across Platinum-Resistant Cancers. Clinical Cancer Research, 2019, 25, 346-357.	7.0	14
60	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. , 2019, , .		3
61	Abstract 2215: SLFN11 and EZH2 protein expression and localization in circulating tumor cells to predict response or resistance to DNA damaging therapies in small cell lung cancer. , 2019, , .		1
62	Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC).. Journal of Clinical Oncology, 2019, 37, TPS8576-TPS8576.	1.6	19
63	Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Reports, 2018, 23, 194-212.e6.	6.4	245
64	Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma. Head and Neck, 2018, 40, 1676-1684.	2.0	9
65	Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiotherapy and Oncology, 2018, 126, 499-505.	0.6	56
66	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer, 2018, 118, 1419-1424.	6.4	7
67	<i>CDKN2A/p16</i> Deletion in Head and Neck Cancer Cells Is Associated with CDK2 Activation, Replication Stress, and Vulnerability to CHK1 Inhibition. Cancer Research, 2018, 78, 781-797.	0.9	37
68	Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Cancer, 2018, 124, 807-815.	4.1	169
69	Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer. Journal of Clinical Oncology, 2018, 36, 2386-2394.	1.6	276
70	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. Translational Lung Cancer Research, 2018, 7, 50-68.	2.8	96
71	<i>eIF</i> <sup>2</sup> , a subunit of translation initiation factor <i>eIF</i> <sup>2</sup> , is a potential therapeutic target for non-small cell lung cancer. Cancer Science, 2018, 109, 1843-1852.	3.9	20
72	Circulating tumor DNA analysis depicts subclonal architecture and genomic evolution of small cell lung cancer. Nature Communications, 2018, 9, 3114.	12.8	122

#	ARTICLE	IF	CITATIONS
73	CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade. <i>Cancer Discovery</i> , 2018, 8, 1156-1175.	9.4	323
74	Integrative proteomic and transcriptomic analysis provides evidence for TrkB (NTRK2) as a therapeutic target in combination with tyrosine kinase inhibitors for non-small cell lung cancer. <i>Oncotarget</i> , 2018, 9, 14268-14284.	1.8	12
75	Abstract 213: Exome sequencing of paired primary and relapsed small cell lung cancers reveals increased copy number aberration complexity to be associated with disease relapse. , 2018, , .		3
76	Durable, exceptional response to temozolomide in a patient with extensive-stage small cell lung cancer (ES-SCLC) metastatic to brain. <i>Cancer Treatment and Research Communications</i> , 2017, 10, 17-20.	1.7	5
77	Giving AXL the axe: targeting AXL in human malignancy. <i>British Journal of Cancer</i> , 2017, 116, 415-423.	6.4	245
78	Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline <i>BRCA1/2</i> Mutations and Selected Sporadic Cancers. <i>Cancer Discovery</i> , 2017, 7, 620-629.	9.4	321
79	Characterization of Human Cancer Cell Lines by Reverse-phase Protein Arrays. <i>Cancer Cell</i> , 2017, 31, 225-239.	16.8	190
80	A murine preclinical syngeneic transplantation model for breast cancer precision medicine. <i>Science Advances</i> , 2017, 3, e1600957.	10.3	10
81	CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. <i>Cancer Research</i> , 2017, 77, 3870-3884.	0.9	163
82	Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 2713-2722.	7.0	91
83	Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. <i>Lancet Oncology</i> , The, 2017, 18, 42-51.	10.7	412
84	CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells. <i>Nature</i> , 2017, 546, 168-172.	27.8	222
85	Identification of proteasomal catalytic subunit <i>PSMA6</i> as a therapeutic target for lung cancer. <i>Cancer Science</i> , 2017, 108, 732-743.	3.9	18
86	HIRA deficiency in muscle fibers causes hypertrophy and susceptibility to oxidative stress. <i>Journal of Cell Science</i> , 2017, 130, 2551-2563.	2.0	9
87	Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6239-6253.	7.0	93
88	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017, 15, 45-58.	3.4	73
89	Germline and Somatic Smoothed Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	3.0	3
90	Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 28575-28587.	1.8	157

#	ARTICLE	IF	CITATIONS
91	A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients. <i>Oncotarget</i> , 2017, 8, 81441-81454.	1.8	12
92	Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. <i>Oncotarget</i> , 2017, 8, 73419-73432.	1.8	74
93	Axl Receptor Axis: A New Therapeutic Target in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1357-1362.	1.1	32
94	Proteomic Profiling Identifies PTK2/FAK as a Driver of Radioresistance in HPV-negative Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 4643-4650.	7.0	64
95	Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer. <i>Gynecologic Oncology</i> , 2016, 141, 588-591.	1.4	53
96	Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression. <i>Oncolmmunology</i> , 2016, 5, e1234570.	4.6	23
97	The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3638-3647.	1.6	140
98	Using reverse-phase protein arrays as pharmacodynamic assays for functional proteomics, biomarker discovery, and drug development in cancer. <i>Seminars in Oncology</i> , 2016, 43, 476-483.	2.2	55
99	Selecting Reliable mRNA Expression Measurements across Platforms Improves Downstream Analysis. <i>Cancer Informatics</i> , 2016, 15, CIN.S38590.	1.9	2
100	Epithelial-Mesenchymal Transition Is Associated with a Distinct Tumor Microenvironment Including Elevation of Inflammatory Signals and Multiple Immune Checkpoints in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3630-3642.	7.0	353
101	Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?. <i>Journal of Thoracic Oncology</i> , 2016, 11, 453-474.	1.1	156
102	Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1674-1686.	7.0	41
103	A Patient-Derived, Pan-Cancer EMT Signature Identifies Global Molecular Alterations and Immune Target Enrichment Following Epithelial-to-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2016, 22, 609-620.	7.0	388
104	Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0152584.	2.5	65
105	Dasatinib induces DNA damage and activates DNA repair pathways leading to senescence in non-small cell lung cancer cell lines with kinase-inactivating BRAF mutations. <i>Oncotarget</i> , 2016, 7, 565-579.	1.8	31
106	drexplorer: A tool to explore dose-response relationships and drug-drug interactions. <i>Bioinformatics</i> , 2015, 31, 1692-1694.	4.1	22
107	Small cell lung cancer: Where do we go from here?. <i>Cancer</i> , 2015, 121, 664-672.	4.1	459
108	Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition. <i>Cancer Cell</i> , 2015, 28, 4-6.	16.8	46

#	ARTICLE	IF	CITATIONS
109	Co-occurring Genomic Alterations Define Major Subsets of <i>KRAS</i> -Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities. <i>Cancer Discovery</i> , 2015, 5, 860-877.	9.4	696
110	Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?. <i>Clinical Cancer Research</i> , 2015, 21, 2244-2255.	7.0	179
111	An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2. <i>Clinical Cancer Research</i> , 2015, 21, 3480-3491.	7.0	48
112	Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. <i>Nature Communications</i> , 2014, 5, 5241.	12.8	780
113	Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin. <i>Cell</i> , 2014, 158, 929-944.	28.9	1,242
114	A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2738-2750.	4.1	72
115	A HER 1-2 Punch: Dual EGFR Targeting Deals Resistance a Deadly Blow. <i>Cancer Discovery</i> , 2014, 4, 991-994.	9.4	13
116	Assessing the clinical utility of cancer genomic and proteomic data across tumor types. <i>Nature Biotechnology</i> , 2014, 32, 644-652.	17.5	257
117	A pan-cancer proteomic perspective on The Cancer Genome Atlas. <i>Nature Communications</i> , 2014, 5, 3887.	12.8	456
118	Identification and Characterization of a Suite of Tumor Targeting Peptides for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2014, 4, 4480.	3.3	44
119	Teaching an Old Dog New Tricks: Drug Repositioning in Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2013, 3, 1333-1335.	9.4	13
120	An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance. <i>Clinical Cancer Research</i> , 2013, 19, 279-290.	7.0	848
121	Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1. <i>Cancer Discovery</i> , 2012, 2, 798-811.	9.4	432
122	Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters. <i>PLoS ONE</i> , 2012, 7, e31087.	2.5	33
123	Proteomic Profiling Identifies Pathways Dysregulated in Non-small Cell Lung Cancer and an Inverse Association of AMPK and Adhesion Pathways with Recurrence. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1894-1904.	1.1	57
124	Serum Signature of Hypoxia-Regulated Factors Is Associated with Progression after Induction Therapy in Head and Neck Squamous Cell Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1755-1763.	4.1	43
125	Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 6852-6861.	7.0	105
126	Dual Targeting of the Vascular Endothelial Growth Factor and Epidermal Growth Factor Receptor Pathways: Rationale and Clinical Applications for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2007, 8, S79-S85.	2.6	68